Aim Vaccine announced on the Hong Kong Stock Exchange on March 17 that it expects to significantly reduce losses. It anticipates recording an unaudited revenue between 1.25 billion to 1.3 billion, which is an increase of 60 million to 0.11 billion compared to last year's revenue of 1.19 billion, representing a growth of 5% to 9%. The company expects to record an unaudited net loss between 0.25 billion to 0.29 billion yuan, which is a significant reduction from last year's net loss of 1.95 billion yuan, reducing losses by 1.66 billion to 1.7 billion, a reduction rate of 85% to 87%. The Board of Directors preliminarily believes that the reason for the increase in revenue is mainly due to the increase in the company's hepatitis B vaccine revenue, and the main reason for the reduction in comprehensive net loss is the decrease in the amount of substantial asset impairment losses this year and the increase in revenue.